Company / SG&A Expense
Enveric Biosciences, Inc. SG&A Expense History
FY2017-FY2019 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$10.8M
FY2019
5-year range
$9.4M / $18.5M
FY2017-FY2019
Trend
-41.7%
vs FY2018
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Increased from $9M to $11M over the past 2 years.
Based on SEC 10-K filings.
$11M in FY2019.
Increased from $9M to $11M over the past 2 years.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2019, sg&a expense decreased 41.7% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2019 | $10.8M | -41.7% |
| FY2018 | $18.5M | +97.7% |
| FY2017 | $9.4M | - |
As of FY2019 · SEC 10-K · Updated Jun 24, 2026